

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

**Proposed Single Technology Appraisal**  
**SGT320 for treating persistent allergic rhinitis caused by house dust mites**  
**ID1278**

## Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<u>Company</u> <ul style="list-style-type: none"> <li>Stallergenes (SGT320)</li> </ul>	<u>General</u> <ul style="list-style-type: none"> <li>Allied Health Professionals Federation</li> <li>All Wales All Wales Therapeutics and Toxicology Centre</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> <li>Care Quality Commission</li> <li>Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>Healthcare Improvement Scotland</li> <li>Medicines and Healthcare Products Regulatory Agency</li> <li>National Association of Primary Care</li> <li>National Pharmacy Association</li> <li>NHS Alliance</li> <li>NHS Confederation</li> <li>Scottish Medicines Consortium</li> <li>Welsh Health Specialised Services Committee</li> </ul>
<u>Patient/carer groups</u> <ul style="list-style-type: none"> <li>Action Against Allergy</li> <li>Allergy UK</li> <li>Asthma Trust for Asthmatic Children</li> <li>Asthma Relief Charity</li> <li>Asthma UK</li> <li>British Lung Foundation</li> <li>European Federation of Allergy and Airways Disease Patients Association</li> <li>Muslim Council of Britain</li> <li>NARA – The Breathing Charity</li> <li>South Asian Health Foundation</li> <li>Specialised Healthcare Alliance</li> </ul>	
<u>Professional groups</u> <ul style="list-style-type: none"> <li>Association of Respiratory Nurse Specialists</li> <li>British Geriatrics Society</li> <li>British Paediatric Respiratory Society</li> <li>British Society for Allergy &amp; Clinical Immunology</li> <li>British Thoracic Society</li> <li>Primary Care Respiratory Society UK</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>UK Clinical Pharmacy Association</li> </ul>	
<u>Others</u> <ul style="list-style-type: none"> <li>Department of Health</li> </ul>	<u>Possible comparator companies</u> <ul style="list-style-type: none"> <li>Accord Healthcare (cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine, mometasone, prednisolone)</li> <li>A. Menarini Farmaceutica (bilastine)</li> <li>AstraZeneca UK (budesonide)</li> <li>Bayer (loratadine)</li> <li>Boehringer Ingelheim (ipratropium)</li> <li>Bristol Laboratories (cetirizine)</li> <li>CD Pharma AB (ketotifen)</li> <li>Crescent Pharma (cetirizine, desloratadine)</li> <li>Dexcel Pharma (cetirizine)</li> <li>Dr Reddy's Laboratories (cetirizine, fexofenadine)</li> </ul>

## Appendix A

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• NHS City and Hackney CCG</li> <li>• NHS England</li> <li>• NHS Solihull CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• GlaxoSmithKline (beclometasone, cetirizine, fluticasone, oxymetazoline, phenylephrine, pseudoephedrine, xylometazoline)</li> <li>• Lupin Europe (desloratadine)</li> <li>• Martindale Pharmaceuticals (betamethasone)</li> <li>• McNeil Products (acrivastine, cetirizine, oxymetazoline, phenylephrine, pseudoephedrine, xylometazoline)</li> <li>• Merck Sharp &amp; Dohme (desloratadine, mometasone)</li> <li>• Mylan (azelastine, beclometasone, desloratadine, fluticasone, levocetirizine, loratadine)</li> <li>• Perrigo UK (beclometasone, cetirizine, pseudoephedrine)</li> <li>• Pfizer (pseudoephedrine)</li> <li>• Pinewood Healthcare (cetirizine, loratadine)</li> <li>• Rosemont Pharmaceuticals (desloratadine)</li> <li>• Sandoz (budesonide, loratadine, mometasone)</li> <li>• Sanofi (fexofenadine, ipratropium, mizolastine)</li> <li>• Sun Pharmaceuticals (loratadine)</li> <li>• Teva UK (beclometasone, cetirizine, fexofenadine, fluticasone, levocetirizine, loratadine, mometasone, prednisolone)</li> <li>• Thornton &amp; Ross (cetirizine, ephedrine, pseudoephedrine)</li> <li>• UCB Pharma (cetirizine, levocetirizine)</li> <li>• Wockhardt UK (cetirizine, ephedrine, prednisolone)</li> <li>• Zentiva (fexofenadine, prednisolone)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Asthma, Allergy and Inflammation Research Trust</li> <li>• British Association for Lung Research</li> <li>• Cochrane Airways Group</li> </ul>

## Appendix A

Consultees	Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"><li>• MRC Clinical Trials Unit</li><li>• National Institute for Health Research</li></ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"><li>• Public Health England</li><li>• Public Health Wales</li></ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

### ***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Determination (FAD).

All non company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland;; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non company commentators are invited to nominate clinical or patient experts.

---

<sup>1</sup> Non company consultees are invited to submit statements relevant to the group they are representing.